Clinical outcomes and time to receipt of CART product in key CAR-T cell therapy clinical trials
| . | Axi-cel . | SOC . | Tisa-cel . | SOC . | Liso-cel . | SOC . |
|---|---|---|---|---|---|---|
| Second-line therapy . | ZUMA-7 . | Belinda . | Transform . | |||
| Received bridging chemotherapy (%) | 0 | — | 83 | — | 63 | — |
| Median time to CAR T-cell infusion (days) | 29 (27-34)* | — | 52 (31-135)† | — | NR | — |
| Received intended ASCT (%) | — | 36 | — | 32.5 | — | 45.6 |
| ORR | 83 | 50 | 46 | 43 | 86 | 48 |
| CR rate | 65 | 32 | 28 | 28 | 66 | 39 |
| EFS, median (months) | 8.3 | 2 | 3 | 3 | 10.1 | 2.3 |
| EFS HR (95% CI) | 0.4 (0.31-0.51) | 1.07 (0.82-1.4) | 0.35 (0.23-0.53) | |||
| PFS, median (months) | 14.7 | 3.7 | NR | NR | 14.8 | 5.7 |
| OS, median (months) | NE | 25.7 | 16.9 | 15.3 | NE | 16.4 |
| Third-line therapy (single-arm trials) . | ZUMA-1 . | JULIET . | TRANSCEND . | |||
| Follow-up, median (months) | 63.1 | — | 40.3 | 23.0 | — | |
| Received bridging chemotherapy (%) | 0 | — | 90 | — | 59 | — |
| Received intended CAR T cell (%) | 91 | — | — | — | ||
| Median time to CAR T-cell infusion (days) | 29 (27-34)* | — | 54 | — | 37 (27-224)† | — |
| ORR | 83% | 53% | — | 73% | — | |
| CR rate | 58% | — | 39% | — | 53% | — |
| Median DOR | 11.1 | — | 3 | — | 23.1 | — |
| Median duration of PR (months) | 1.9 | — | — | — | — | |
| Duration of CR (months) | 62.2 | — | 0.35 (0.23-0.53) | — | 26.1 | — |
| EFS, median (months) | 5.7 | — | NR | — | ||
| PFS, median (months) | 5.9 | — | — | 6.8 | — | |
| OS, median (months) | NR | 11.1 | 27.3 | — | ||
| . | Axi-cel . | SOC . | Tisa-cel . | SOC . | Liso-cel . | SOC . |
|---|---|---|---|---|---|---|
| Second-line therapy . | ZUMA-7 . | Belinda . | Transform . | |||
| Received bridging chemotherapy (%) | 0 | — | 83 | — | 63 | — |
| Median time to CAR T-cell infusion (days) | 29 (27-34)* | — | 52 (31-135)† | — | NR | — |
| Received intended ASCT (%) | — | 36 | — | 32.5 | — | 45.6 |
| ORR | 83 | 50 | 46 | 43 | 86 | 48 |
| CR rate | 65 | 32 | 28 | 28 | 66 | 39 |
| EFS, median (months) | 8.3 | 2 | 3 | 3 | 10.1 | 2.3 |
| EFS HR (95% CI) | 0.4 (0.31-0.51) | 1.07 (0.82-1.4) | 0.35 (0.23-0.53) | |||
| PFS, median (months) | 14.7 | 3.7 | NR | NR | 14.8 | 5.7 |
| OS, median (months) | NE | 25.7 | 16.9 | 15.3 | NE | 16.4 |
| Third-line therapy (single-arm trials) . | ZUMA-1 . | JULIET . | TRANSCEND . | |||
| Follow-up, median (months) | 63.1 | — | 40.3 | 23.0 | — | |
| Received bridging chemotherapy (%) | 0 | — | 90 | — | 59 | — |
| Received intended CAR T cell (%) | 91 | — | — | — | ||
| Median time to CAR T-cell infusion (days) | 29 (27-34)* | — | 54 | — | 37 (27-224)† | — |
| ORR | 83% | 53% | — | 73% | — | |
| CR rate | 58% | — | 39% | — | 53% | — |
| Median DOR | 11.1 | — | 3 | — | 23.1 | — |
| Median duration of PR (months) | 1.9 | — | — | — | — | |
| Duration of CR (months) | 62.2 | — | 0.35 (0.23-0.53) | — | 26.1 | — |
| EFS, median (months) | 5.7 | — | NR | — | ||
| PFS, median (months) | 5.9 | — | — | 6.8 | — | |
| OS, median (months) | NR | 11.1 | 27.3 | — | ||
interquartile range.
range.
ASCT, autologous stem cell transplant; CAR, chimeric antigen receptor; CR, complete response; DOR, duration of remission; EFS, event-free survival; HR, high risk; NE, neutrophil elastase; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; SOC, standard of care.